InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
make it happen Free
08/24/21 8:39 AM
profile icon
INFINITI Free
08/24/21 7:52 AM
profile icon
Warrens Free
04/21/21 6:49 PM
profile icon
Warrens Free
04/20/21 12:12 PM
profile icon
ClayTrader Free
04/05/21 4:49 PM
profile icon
Iron heart Free
03/03/21 3:58 AM
profile icon
Roadtojourney Free
02/16/21 4:53 PM
profile icon
Paullee Free
02/11/21 11:05 AM
profile icon
Roadtojourney Free
02/11/21 10:50 AM
profile icon
ClayTrader Free
02/10/21 4:38 PM
profile icon
Stock_Barber PremiumMember
02/10/21 12:56 PM
profile icon
Hercules1 Free
02/10/21 12:01 PM
profile icon
NicksterPDX Free
02/10/21 10:57 AM
profile icon
cfoofme Free
02/10/21 9:54 AM
profile icon
NicksterPDX Free
02/10/21 9:52 AM
profile icon
cfoofme Free
02/10/21 9:50 AM
profile icon
jonny_red Free
01/06/21 8:34 AM
profile icon
jonny_red Free
01/05/21 3:00 PM
profile icon
zino Free
01/05/21 11:08 AM
profile icon
sanderburwil Free
12/09/20 3:15 PM
profile icon
mik1234 Free
11/20/20 1:57 PM
profile icon
blairsoldman Free
11/19/20 11:39 AM
profile icon
alex1940 Free
11/06/20 8:59 AM
profile icon
SloDan Free
11/05/20 5:12 PM
profile icon
NicksterPDX Free
10/29/20 11:58 AM
profile icon
ClayTrader Free
10/22/20 6:12 PM
profile icon
whytestocks Free
10/22/20 12:30 PM
profile icon
Biggeoff Free
10/22/20 12:17 PM
profile icon
whytestocks Free
10/22/20 12:15 PM
profile icon
blairsoldman Free
10/22/20 10:31 AM
profile icon
Paullee Free
10/22/20 7:15 AM
profile icon
Awl416 Free
10/22/20 7:12 AM
profile icon
makingitnow Free
09/18/20 5:36 PM
profile icon
SloDan Free
09/16/20 11:59 AM
profile icon
blairsoldman Free
09/10/20 9:53 PM
profile icon
blairsoldman Free
09/09/20 9:38 AM
profile icon
SJSTOCKSHARK Free
09/04/20 3:11 PM
profile icon
benchman PremiumMember
08/24/20 11:40 AM
profile icon
ClayTrader Free
08/21/20 5:51 PM
profile icon
kingsplay Free
08/21/20 5:22 PM
profile icon
Paullee Free
08/21/20 1:31 PM
profile icon
whytestocks Free
08/21/20 1:30 PM
profile icon
Paullee Free
08/21/20 12:29 PM
profile icon
kingsplay Free
08/21/20 11:02 AM
profile icon
whytestocks Free
08/13/20 5:00 PM

Bio Path Holdings Inc (BPTH) RSS Feed

Followers
101
Posters
339
Posts (Today)
0
Posts (Total)
6377
Created
03/26/13
Type
Free
Moderators




Bio-Path is engaged in the business of financing and commercializing novel cancer therapeutics acquired from MD Anderson Cancer Center. Their first Antisense drug BP-1001, known as Prexigebersen has completed a partial phase II combination trial (with LDAC). The interim results demonstrated 47% of the patients showed early anti-leukemic activity.


http://www.biopathholdings.com/wp-content/uploads/2018/04/BPTH_Interim_Phase_2_AML_Data_Release.pdf 

The Prexigebersen phase II trials for AML are located at MD Anderson, Weill Cornell Medical College Presbyterian Hospital, Baylor, New Jersey Hematology Oncology Associates, West Virginia University and University of Kansas.

Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug, Prexigebersen is targeting the Grb-2 protein. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the phase 2 of the combination trial for Prexigebersen there has been absolutely no toxicity. The results of testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating the delivery system. The purpose of phase 2 will be to test the effectiveness of the drug. Interim results are positive.

A CML combination drug safety study with Sprycel (Dasatinib) for Prexigebersen has begun at MD Anderson.

Patent protection for manufacturing their neutral lipid delivery system has been granted.


http://www.biopathholdings.com

This link to the company website describes their delivery technology:


http://biopathholdings.com/technology/


The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson is the largest insitutional shareholder. After raising additional funds the company has 2+ million in cash. BIO-PATH'S viability is in question due to a lack of funds.

 
Bio-Path Holdings does not manufacture their drugs but uses contractors, hence the need for partners.
 
BPTH is presently traded on the NASDAQ.

Here are links to articles on their drug technology:


http://www.abstractsonline.com/pp8/#!/4292/presentation/2610

http://www.biopathholdings.com/wp-content/uploads/2017/06/Published-Article-Evolution-of-Antisense-in-Oncology.pdf

http://www.biopathholdings.com/wp-content/uploads/2018/03/BPTH_Lancet_20180329.pdf


Stone Gate Capital "under valued"
https://finance.yahoo.com/news/stonegate-capital-partners-updates-coverage-213000664.html        
https://investorshub.advfn.com/75fb7cf5-a8b2-4eb3-b48e-3bb1403ff45a"="" rel="nofollow" target="_blank">; style="height:1.200000; width:234.840000">

Our press releases-See Links here
http://www.biopathholdings.com/press-release/


Bio-Path Holdings, Inc. Announces $18.5 Million Registered Direct Offering of Common Stock

 
 

 

New Post